Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

Inclusion Criteria Histologically or cytologically confirmed diagnosis of ovarian cancer Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel) At least 18 years of age Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. Karnofsky performance status of at least 70% Estimated life expectancy of at least 12 weeks Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive Subject must be able to comply with study procedures and follow-up examinations. Signed written informed consent Lab Values (obtained ≤ 7 days prior to study enrollment): ANC at least 1.5x10e9/L, Platelet count at least 100x10e9/L, Hemoglobin at least 8.5 g/dL, Creatinine within 2 times upper limit of normal AST and ALT within 3 times upper limit of normal Bilirubin within 1.5 times upper limit of normal Albumin great than 2.5 g/dL INR < 1.5 for subjects without anticoagulants Exclusion Criteria Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms Patients who have received any investigational agent within 4 weeks of enrollment Patients who are pregnant or breast-feeding History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix History of central nervous system metastases or carcinomatous meningitis Major surgery within 4 weeks of enrollment